Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Abby Van Voorhees MD, FAAD

Abby S. Van Voorhees MD, FAAD

Professor and Chair, Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia

Abby S. Van Voorhees, M.D., is a professor and chair of the department of dermatology at the Eastern Virginia Medical School in Norfolk, Virginia. She obtained her B.A. from Brown University in 1979 in biology and received her M.D. from Yale University in 1983. She completed her dermatology residency at the Yale-New Haven Hospital in 1988, serving as the chief resident from July 1987 to 1988. In addition to her current position, Dr. Van Voorhees has also worked in the University of Pennsylvania and the University of Connecticut, Department of Medicine. She has been active in clinical research issues in dermatology, particularly those related to the treatment of psoriasis. She currently also is the Medical Editor of Dermatology World. Dr. Van Voorhees is the chair of the Medical Board of the National Psoriasis Foundation. She has served on several of the American Academy of Dermatology’s committees and task forces, including serving as the chairman for the Guidelines of Care task force. She is the author of 85 publications.

Recent Contributions to PracticeUpdate:

  1. Effectiveness of 16-Week vs 8-Week Guselkumab Dosing in Maintaining Psoriasis Control in Super Responders
  2. Screening and Management of Patients With Psoriatic Arthritis
  3. Efficacy and Safety of Oral Tyrosine Kinase 2 Inhibitor PF-06826647 in Managing Moderate to Severe Plaque Psoriasis
  4. The Impact of COVID-19 on Patients With Chronic Plaque Psoriasis Treated With Biological Therapy
  5. Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis
  6. All-Cause and Cause-Specific Mortality in Psoriasis
  7. Adherence to the Mediterranean Diet and Severity of Psoriasis
  8. Psoriatic Patients With Chronic Viral Hepatitis Do Not Have an Increased Risk of Cirrhosis Despite Long-Term MTX Use
  9. Pediatric Psoriasis Comorbidity Screening Guidelines
  10. Comparative Effectiveness of Biologic Agents for Psoriasis in a Real-World Setting

Most Read This Week

Recently Updated